Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

La Merie Publishing released on March 8, 2020 the 14th edition of reports about sales of Blockbuster Biologics. This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2019. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 4, 2020. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).

A total of 55 biologic therapeutics reached blockbuster status with 2019 sales exceeding US$ 1 bln: 36 antibodies and 19 proteins. Antibody sales represented more than 70% of total biologics sales in 2019. Elven biologics reached global sales in 2019 of more than US$ 5 bln. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2019 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2019.